ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 109 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 1.92 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $154,000 | +65.6% | 7,649 | +132.1% | 0.00% | – |
| Q2 2023 | $93,000 | +102.2% | 3,296 | +22.9% | 0.00% | – |
| Q1 2023 | $46,000 | -71.4% | 2,681 | -66.2% | 0.00% | – |
| Q4 2022 | $161,000 | +1138.5% | 7,930 | +1228.3% | 0.00% | – |
| Q3 2022 | $13,000 | -96.8% | 597 | -95.9% | 0.00% | – |
| Q2 2022 | $409,000 | -46.4% | 14,553 | -12.0% | 0.00% | – |
| Q1 2022 | $763,000 | -60.3% | 16,546 | -27.7% | 0.00% | – |
| Q4 2021 | $1,924,000 | +736.5% | 22,893 | +562.8% | 0.00% | – |
| Q3 2021 | $230,000 | +90.1% | 3,454 | +51.8% | 0.00% | – |
| Q2 2021 | $121,000 | +17.5% | 2,276 | -3.8% | 0.00% | – |
| Q1 2021 | $103,000 | +194.3% | 2,365 | +254.0% | 0.00% | – |
| Q4 2020 | $35,000 | +3400.0% | 668 | +2469.2% | 0.00% | – |
| Q3 2020 | $1,000 | 0.0% | 26 | +18.2% | 0.00% | – |
| Q2 2020 | $1,000 | – | 22 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Paradigm Biocapital Advisors LP | 300,434 | $25,254,000 | 7.21% |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,628,409 | $220,944,000 | 6.56% |
| Avidity Partners Management LP | 2,715,000 | $228,223,000 | 4.84% |
| Matrix Capital Management Company, LP | 4,349,279 | $365,600,000 | 4.07% |
| Affinity Asset Advisors, LLC | 117,500 | $9,877,000 | 3.59% |
| Integral Health Asset Management, LLC | 120,000 | $10,087,000 | 2.79% |
| Ghost Tree Capital, LLC | 80,000 | $6,725,000 | 2.41% |
| Ikarian Capital, LLC | 191,140 | $16,067,000 | 2.39% |
| Tri Locum Partners LP | 23,632 | $1,987,000 | 0.78% |
| Eventide Asset Management | 529,000 | $44,468,000 | 0.57% |